Ayurcann Holdings Corp. (AYUR) AI Stock Analysis

• Market Cap: C$3.89M
• Dividend Yield: N/A
• Average Volume (3M): 59.98K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.58
• Revenue Growth: 15.95%
• EPS Growth: -1.81%
• Country: CA
• Employees: N/A
• Sector: N/A
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 194,703,860
• 10 Day Avg. Volume: 17,939
• 30 Day Avg. Volume: 59,984
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: C$0.02 ▲(20.00% Upside)

The overall stock score is primarily driven by financial performance challenges, including high leverage and negative equity, which overshadow strong revenue growth. Technical analysis indicates a bearish trend, and valuation metrics show limited appeal due to ongoing losses.

Ayurcann Holdings Corp. Business Overview & Revenue Model

Company Description

Ayurcann Holdings Corp. (AYUR) is a Canadian company specializing in the production and distribution of cannabis-derived products, focusing on innovative formulations that cater to both the medical and recreational markets. The company operates primarily in the cannabis sector, offering a range of products including oils, capsules, and edibles, with an emphasis on quality and sustainability. Ayurcann is committed to leveraging its proprietary extraction technology and product development capabilities to meet the evolving needs of consumers in the burgeoning cannabis industry.

How the Company Makes Money

Ayurcann Holdings Corp. generates revenue through several key streams, primarily from the sale of its cannabis products, which include oils, capsules, and edibles. The company benefits from its proprietary extraction technologies, allowing it to produce high-quality cannabis extracts that can be sold to other businesses or used in its own product lines. Additionally, Ayurcann may engage in partnerships with licensed producers and retailers, creating collaborative opportunities that enhance distribution and market reach. The company also explores potential joint ventures and agreements with other players in the cannabis sector, which can provide further revenue opportunities and a broadened customer base.

Ayurcann Holdings Corp. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Ayurcann Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AYUR, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.93 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AYUR.

Ayurcann Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
RVV	46 Neutral	C$4.19M	-0.39	-664.21%	―	―	-80.42%
SE	40 Underperform	C$6.59M	-3.63	―	―	-100.00%	-192.62%
AYUR	38 Underperform	C$3.89M	-1.11	-271.33%	―	15.95%	-1.81%
LOBE	38 Underperform	C$9.66M	-1.67	―	―	-100.00%	-8.70%
MVMD	35 Underperform	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
PCLO	24 Underperform	$6.92M	-1.26	―	―	15.64%	58.47%

Ayurcann Holdings Corp. Corporate Events

Ayurcann Holdings Corp. Reports Record Q3 2025 Growth and Expands Market Presence

Ayurcann Holdings Corp. reported record-breaking financial results for Q3 2025, with a gross revenue of $14,179,974, marking a 22% year-over-year increase. The company has achieved significant market share, being a top 3 vape producer in Ontario and holding a 5% national market share. With a focus on operational efficiency and a growing national footprint, Ayurcann is well-positioned for sustainable growth, despite industry challenges. The company is actively expanding its product categories and geographic reach to drive future revenue growth.